Abstract
Introduction There were concerns that suicide deaths might increase due to Covid-19 pandemic-related stressors. Previous research demonstrated that suicide deaths actually decreased in 2020 in the US. An update covering 2021-2022 with regional data is warranted.
Methods Observational cohort, US and regional data. Expected monthly deaths were modeled using pre-pandemic US and regional data (2015-2020). Mortality data was accessed from CDC public reporting.
Results We find that suicide deaths in the United States were below expected levels throughout the pandemic period (March 1, 2020-June 30,2022) with >4,100 fewer suicide deaths than would have been expected to occur during the study period. Stratifying suicide mortality by US Census Bureau region yielded statistically significant decreases from expected suicide deaths in all regions except the Midwest, (which recorded no significant change in suicide deaths during the overall pandemic period).
Conclusion Suicide mortality is down in the US since the pandemic began, through June 30, 2022. Possible explanations include an early “coming together” effect; Later, increased access to mental health resources and a greater focus on mental health in the media may have reduced stigma and barriers in seeking necessary psychiatric care.
Competing Interest Statement
Dr. Krumholz reported receiving consulting fees from UnitedHealth, Element Science, Aetna, Reality Labs, F-Prime, and Tesseract/4Catalyst; serving as an expert witness for Martin/Baughman law firm, Arnold and Porter law firm, and Siegfried and Jensen law firm; being a cofounder of Hugo Health, a personal health information platform; being a cofounder of Refactor Health, an enterprise health care, artificial intelligence-augmented data management company; receiving contracts from the Centers for Medicare & Medicaid Services through Yale New Haven Hospital to develop and maintain performance measures that are publicly reported; and receiving grants from Johnson & Johnson outside the submitted work. No other disclosures were reported.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used publicly available data from CDC WONDER and was not subject to institutional review approval per HHS regulation 45 CFR 46.101(c). https://wonder.cdc.gov/mcd-icd10-provisional.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
